Shopping Cart
Remove All
Your shopping cart is currently empty
Ficlatuzumab
Catalog No. T76745 Copy Product Info
🥰Excellent
Ficlatuzumab is a humanized monoclonal antibody that specifically targets and neutralizes the biological activity of human hepatocyte growth factor (HGF), by inhibiting HGF, Ficlatuzumab effectively blocks c-Met receptor-mediated downstream signaling pathways responsible for cancer cell proliferation, migration, and invasion, demonstrating applicable use for the treatment of squamous cell carcinoma.
Ficlatuzumab
Copy Product Info🥰Excellent
Catalog No. T76745
Ficlatuzumab is a humanized monoclonal antibody that specifically targets and neutralizes the biological activity of human hepatocyte growth factor (HGF), by inhibiting HGF, Ficlatuzumab effectively blocks c-Met receptor-mediated downstream signaling pathways responsible for cancer cell proliferation, migration, and invasion, demonstrating applicable use for the treatment of squamous cell carcinoma.
Ficlatuzumab
Cas No. 1174900-84-5
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $147 | - | In Stock | |
| 5 mg | $446 | - | In Stock | |
| 10 mg | $762 | - | In Stock | |
| 25 mg | $1,130 | - | In Stock | |
| 50 mg | $1,530 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.0% (SDS-PAGE); 99.0% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ficlatuzumab is a humanized monoclonal antibody that specifically targets and neutralizes the biological activity of human hepatocyte growth factor (HGF), by inhibiting HGF, Ficlatuzumab effectively blocks c-Met receptor-mediated downstream signaling pathways responsible for cancer cell proliferation, migration, and invasion, demonstrating applicable use for the treatment of squamous cell carcinoma. |
| In vitro | Ficlatuzumab (20 μg/mL, 24 hours) treatment of HNSCC cells can effectively reduce the migration and invasion of HNSCC cells promoted by tumor-associated fibroblast (TAF) culture medium, and can also reduce the epithelial-mesenchymal transition (EMT) and vimentin expression of HNSCC cells promoted by TAF. [1] |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | HGF/SF |
| Molecular Weight | 145.39 kDa |
| Cas No. | 1174900-84-5 |
| Isotype | IgG1 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Ficlatuzumab | purchase Ficlatuzumab | Ficlatuzumab cost | order Ficlatuzumab | Ficlatuzumab in vitro | Ficlatuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.